Galectin Therapeutics | GALT - Debt


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Galectin Therapeutics

Galectin Therapeutics reported $49.94M in Debt for its fiscal quarter ending in March of 2023.


Debt Change
Bristol-Myers Squibb BMY:US USD 37.83B 1.49B
Galectin Therapeutics GALT:US USD 49.94M 10.11M
Incyte Corp INCY:US USD 32.85M 414K
Intercept Pharmaceuticals ICPT:US USD 333.04M 367K
Regulus Therapeutics RGLS:US USD 3.72M 795K